ArQule (NASDAQ: ARQL) recently received a number of ratings updates from brokerages and research firms:

  • 6/5/2019 – ArQule was given a new $11.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 5/31/2019 – ArQule was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
  • 5/29/2019 – ArQule had its price target raised by analysts at B. Riley from $6.75 to $11.00. They now have a “buy” rating on the stock.
  • 5/28/2019 – ArQule had its “buy” rating reaffirmed by analysts at Roth Capital.
  • 5/24/2019 – ArQule was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 5/7/2019 – ArQule was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
  • 5/2/2019 – ArQule was given a new $10.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 4/30/2019 – ArQule was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 4/19/2019 – ArQule was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of NASDAQ ARQL traded up $0.11 during midday trading on Wednesday, reaching $6.35. 37,852 shares of the company’s stock were exchanged, compared to its average volume of 1,440,612. ArQule, Inc. has a 52-week low of $2.23 and a 52-week high of $7.93. The firm has a market cap of $671.71 million, a price-to-earnings ratio of -39.69 and a beta of 1.95. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.45 and a current ratio of 6.45.

ArQule (NASDAQ:ARQL) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($0.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.01). The firm had revenue of $1.35 million during the quarter, compared to analyst estimates of $1.70 million. ArQule had a negative return on equity of 28.90% and a negative net margin of 83.15%. As a group, research analysts predict that ArQule, Inc. will post -0.37 EPS for the current year.

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in ArQule by 59.9% during the third quarter. Vanguard Group Inc. now owns 5,991,497 shares of the biotechnology company’s stock worth $33,912,000 after buying an additional 2,245,325 shares during the last quarter. BlackRock Inc. grew its holdings in ArQule by 26.6% during the 4th quarter. BlackRock Inc. now owns 8,618,012 shares of the biotechnology company’s stock worth $23,872,000 after acquiring an additional 1,808,657 shares during the last quarter. Federated Investors Inc. PA grew its holdings in ArQule by 35,596.1% during the 1st quarter. Federated Investors Inc. PA now owns 700,000 shares of the biotechnology company’s stock worth $3,353,000 after acquiring an additional 698,039 shares during the last quarter. Citigroup Inc. grew its holdings in ArQule by 953.8% during the 4th quarter. Citigroup Inc. now owns 584,279 shares of the biotechnology company’s stock worth $1,618,000 after acquiring an additional 528,836 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in ArQule during the 1st quarter worth approximately $1,567,000. Institutional investors own 72.21% of the company’s stock.

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.

Recommended Story: Why do companies pay special dividends?

Receive News & Ratings for ArQule Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc and related companies with MarketBeat.com's FREE daily email newsletter.